Oncology is one of the most intricate segments of medical science. It is the branch of medical science that deals with the prevention, diagnosis, and treatment of cancer.
The process of oncology requires precision instruments to eliminate the cancerous cells from the human body.
The oncology market has seen robust growth in recent years. Due to this, this market is experiencing a huge inflow of capital and support from governing bodies.
One of the many companies that have seen growth is Repare Therapeutics Inc.
Based in Canada, Repare Therapeutics is an industry leader oncology company engaged in clinical-stage precision.
Repare Therapeutics Inc is an oncology-based company dedicated to the development of precision therapeutics. The company uses the SNIPRx platform that is CRISPR-enabled for the discovery and development of aimed therapies for cancer.
These therapies focus on detecting instability in genomes which also include repairs in DNA damage.
With Repair Therapeutics, it has become easy to cope with tumor biology that was previously not targeted. The company suggests using an approach that focuses on specified genetics and enables its operation to various tumors.
Genetic stratification of patients enables higher response rates.
Using its platform, Repare Therapeutics Inc is developing a pipeline of S.L. product candidates. One of them is their product, RP-3500, which is an oral small cell inhibitor that is used to treat solid tumors that contain DNA damage repair-related alterations in the genomes.
The company uses a gene-editing technology alongside their target discovery method with clinical informatics, high-resolution protein crystallography, and computational biology.
It enables patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.
In order to get more insights into the company, you need to know what the company aims to provide to the community. Its mission, ethics, and scientific methodology play a crucial role in understanding the unique approach of Repare Therapeutics.
Repair Therapeutics is a pioneering synthetic lethality to develop novel therapeutics. They target specific vulnerabilities of tumors in genetically defined inpatient populations.
The company’s initial focus is on novel targeted therapies in cancer types harboring defective DNA-damage response (DDR)- or genome instability-related functions.
High standards have been set by the Board of Directors of Repair Therapeutics for the employees and officers of the company. What’s included in this doctrine is the significance of great corporate governance.
The Board of Directors must serve as an insightful fiduciary to the company’s shareholders and watch out for the company’s business management.
In order to perform the responsibility and duties, the company’s Board of Directors follows a set of rules and standards outlined in the guidelines.
The company guidelines are subject to modification and additional regulations. As and when the Board of Directors deems appropriate, these modifications are made. They are done in the company’s best interests or as required by the applicable laws and regulations.
Repair Therapeutics is an industry-leading oncology company engaged in clinical-stage precision. The company is considered to be the leader in the field of genomic instability and screening approaches for synthetic lethality (S.L.).
The company’s management team is highly qualified with broad experience in drug discovery and development of drugs.
The co-founders and other executive team members have extensive aggregated experience in the discovery of oncology drugs and their development.
Found in 2016, Repare Therapeutics Inc is a publicly held company. Over two rounds, Repare Therapeutics has been able to raise a total of $150.5M in funding. Their latest funding was raised on September 4, 2019, from a Series B round.
- Estimated Revenue
Repair Therapeutics’ estimated annual revenue is currently $15.8M per year.
The estimated revenue per employee of Repare Therapeutics is $155,000.
- Cash and restricted cash
Cash and restricted cash as of June 30, 2020, was $370.1 million.
- Research and development expenses, net of tax credits (Not R&D)
Net R&D expenses were $9.0 million and $17.6 million for the three and six-month periods ended June 30, 2020, compared to $4.9 million and $8.6 million in the same periods in the prior year, respectively.
- General and administrative (G&A) expenses
G&A expenses were $3.4 million and $5.4 million for the three and six-month periods ended June 30, 2020, as compared to $1 million and $2.1 million in the same periods in the prior year, respectively.
The stock symbol of Repare Therapeutics is RPTX. The company’s shares are traded on the Nasdaq Global Select Market. Repair Therapeutics’ CUSIP number is 760273 102. The company went public on September 6, 2016.
One share of RPTX stock can currently be purchased for approximately $33.14.
Repair Therapeutics’ initial public offering was on June 18, 2020. Money Raised at IPO was $220M.
Top Institutions Investors Of Repare Therapeutics
- BVF Inc.
- Orbimed Advisors LLC.
- FMR, LLC
- Redmile Group, LLC
- MPM Asset Management, LLC
- CHI Advisors LLC
- MPM ONCOLOGY IMPACT MANAGEMENT LP
- ARK Investment Management, LLC
- Logos Global Management LP
- Artal Group S.A.
The company systematically analyzes genomic data of around 60,000 samples of the tumor. The samples are then identified as the beginning set of tumor genomic alterations, which are referred to as tumor lesions.
They complete a SNIPRx screen platform to identify the targets which were reported previously or even the unreported ones for each of these tumor lesions.
The SNIPRx screen campaigns identify multiple potential targets. This allows them to prioritize and select targets to advance into drug discovery based on a systematic and proprietary set of criteria.
Repare Therapeutics Inc is a growing name in the oncology market. And it is owing to its unique scientific methodology and approach. Even though the company is facing strong competition from the competitors, Repare Therapeutics Inc definitely has a promising road ahead.